Vantis Vascular, Inc. has completed the Series B-1 preferred financing round, raising $10 million and overall funding reached $30 million. Some investors include high-net-worth individuals and NIH grants. The founder and the CEO of Vantis Vascular, Jason Turner, noted this achievement meaningfully: This funding will help us proceed with product dev, expand our team, and start the US comm of CrossFAST Advanced Delivery System for intricate, high-risk PCI interventions.